Ali Wakil
Hepatology · Newark, NJNPI 1730609637
Payments from drug & device makers
Across 128 payments — averaging $58.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$2K
- Madrigal Pharmaceuticals$703
- Johnson & Johnson$673
- Olympus Corporation Of The Americas$638
- Phathom Pharmaceuticals, Inc.$398
- plus $1K from 17 others
What the payments were for
- Travel & lodging$6038%
- Food & beverage$6,78690%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $2,478 |
| Gilead | 29 | $1,601 |
| Madrigal Pharmaceuticals | 10 | $703 |
| Johnson & Johnson | 11 | $673 |
| Olympus Corporation Of The Americas | 8 | $638 |
| Phathom Pharmaceuticals, Inc. | 3 | $398 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $162 |
| Novo Nordisk | 2 | $140 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Celltrion USA Inc. | 4 | $105 |
| Fujifilm Healthcare Americas Corporation | 1 | $85 |
| Bristol Myers Squibb | 3 | $68 |
| Medtronic | 1 | $65 |
| Boehringer Ingelheim | 1 | $34 |
| Lilly USA, LLC | 2 | $34 |
| Dynavax Technologies Corporation | 1 | $31 |
| Ardelyx, Inc. | 1 | $31 |
| Braintree Laboratories, Inc. | 1 | $26 |
| Micro-tech Endoscopy USA, Inc. | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Capsovision, Inc. | 1 | $22 |
| Orphalan Inc | 1 | $21 |
| Avanos Medical | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavyret$943
- Single Use Biliary Balloon Dilator$545
- REZDIFFRA$432
- Tremfya$410
- Skyrizi$399
- VOQUEZNA$398
- Epclusa$375
- Livdelzi$241
- Vemlidy$239
- Rinvoq$149
- RESMETIROM$142
- ZEPOSIA$125
- VIBERZI$125
- HANAROSTENT Esophagus TTS(CCC)$102
How this compares
Too few hepatology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 19 | $62,577 |
| Lactulose | 14 | $20,956 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 63 | $3,309 |
| Tenofovir Disoproxil Fumarate | 16 | $1,462 |
| Omeprazole | 44 | $479 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 33 | $432 |
| Pantoprazole Sodium | 77 | $412 |
| Famotidine | 22 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $24 | $62,57719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other hepatology in Newark
- Maliha AhmadNewark$557K
- Mumtaz NiaziNewark$25K
- Raquel Olivo VillabrilleNewark$146
- Ben daJersey City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.